ORYZF Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -- compared to Oryzon Genomics SA's net margin of --. Oryzon Genomics SA's return on equity of -2.73% beat CEL-SCI Corp.'s return on equity of -266.61%.

Oryzon Genomics SA has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that CEL-SCI Corp. has higher upside potential than Oryzon Genomics SA, analysts believe CEL-SCI Corp. is more attractive than Oryzon Genomics SA.

Oryzon Genomics SA has a beta of 0.396, which suggesting that the stock is 60.368% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Oryzon Genomics SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oryzon Genomics SA pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Oryzon Genomics SA quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Oryzon Genomics SA's net income of $393.5K is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Oryzon Genomics SA's price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oryzon Genomics SA is 440.67x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Grifols SA has a net margin of -- compared to Oryzon Genomics SA's net margin of 7.69%. Oryzon Genomics SA's return on equity of -2.73% beat Grifols SA's return on equity of 5.73%.

Oryzon Genomics SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Grifols SA has an analysts' consensus of $11.25 which suggests that it could grow by 27.12%. Given that Grifols SA has higher upside potential than Oryzon Genomics SA, analysts believe Grifols SA is more attractive than Oryzon Genomics SA.

Oryzon Genomics SA has a beta of 0.396, which suggesting that the stock is 60.368% less volatile than S&P 500. In comparison Grifols SA has a beta of 0.671, suggesting its less volatile than the S&P 500 by 32.935%.

Oryzon Genomics SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Grifols SA offers a yield of 1.96% to investors and pays a quarterly dividend of $0.17 per share. Oryzon Genomics SA pays -- of its earnings as a dividend. Grifols SA pays out -- of its earnings as a dividend.

Oryzon Genomics SA quarterly revenues are --, which are smaller than Grifols SA quarterly revenues of $2.2B. Oryzon Genomics SA's net income of $393.5K is lower than Grifols SA's net income of $167.6M. Notably, Oryzon Genomics SA's price-to-earnings ratio is -- while Grifols SA's PE ratio is 14.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oryzon Genomics SA is 440.67x versus 0.72x for Grifols SA. Usually stocks with elevated PS ratios are considered overvalued.

Laboratorios Farmaceúticos Rovi SA has a net margin of -- compared to Oryzon Genomics SA's net margin of 27.56%. Oryzon Genomics SA's return on equity of -2.73% beat Laboratorios Farmaceúticos Rovi SA's return on equity of 20.71%.

Oryzon Genomics SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Laboratorios Farmaceúticos Rovi SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Oryzon Genomics SA has higher upside potential than Laboratorios Farmaceúticos Rovi SA, analysts believe Oryzon Genomics SA is more attractive than Laboratorios Farmaceúticos Rovi SA.

Oryzon Genomics SA has a beta of 0.396, which suggesting that the stock is 60.368% less volatile than S&P 500. In comparison Laboratorios Farmaceúticos Rovi SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Oryzon Genomics SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Laboratorios Farmaceúticos Rovi SA offers a yield of 1.66% to investors and pays a quarterly dividend of $1.09 per share. Oryzon Genomics SA pays -- of its earnings as a dividend. Laboratorios Farmaceúticos Rovi SA pays out 28.3% of its earnings as a dividend. Laboratorios Farmaceúticos Rovi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Oryzon Genomics SA quarterly revenues are --, which are smaller than Laboratorios Farmaceúticos Rovi SA quarterly revenues of $245.9M. Oryzon Genomics SA's net income of $393.5K is lower than Laboratorios Farmaceúticos Rovi SA's net income of $67.8M. Notably, Oryzon Genomics SA's price-to-earnings ratio is -- while Laboratorios Farmaceúticos Rovi SA's PE ratio is 24.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oryzon Genomics SA is 440.67x versus 4.20x for Laboratorios Farmaceúticos Rovi SA. Usually stocks with elevated PS ratios are considered overvalued.

Pharma Mar SA has a net margin of -- compared to Oryzon Genomics SA's net margin of -11.5%. Oryzon Genomics SA's return on equity of -2.73% beat Pharma Mar SA's return on equity of 17.03%.

Oryzon Genomics SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Pharma Mar SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Oryzon Genomics SA has higher upside potential than Pharma Mar SA, analysts believe Oryzon Genomics SA is more attractive than Pharma Mar SA.

Oryzon Genomics SA has a beta of 0.396, which suggesting that the stock is 60.368% less volatile than S&P 500. In comparison Pharma Mar SA has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.224%.

Oryzon Genomics SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharma Mar SA offers a yield of 0% to investors and pays a quarterly dividend of $0.92 per share. Oryzon Genomics SA pays -- of its earnings as a dividend. Pharma Mar SA pays out 43.51% of its earnings as a dividend. Pharma Mar SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Oryzon Genomics SA quarterly revenues are --, which are smaller than Pharma Mar SA quarterly revenues of $41.7M. Oryzon Genomics SA's net income of $393.5K is higher than Pharma Mar SA's net income of -$4.8M. Notably, Oryzon Genomics SA's price-to-earnings ratio is -- while Pharma Mar SA's PE ratio is 40.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oryzon Genomics SA is 440.67x versus 7.65x for Pharma Mar SA. Usually stocks with elevated PS ratios are considered overvalued.